Attenuation of adrenergic drive and cognitive enhancement, via stimulation of alpha2 pre- and post-synaptic receptors, may selectively enhance executive performance in early abstinent cocaine-dependent individuals. As these cognitive processes underpin important treatment-related behaviors, the alpha2 agonist, guanfacine HCl, may represent an effective pharmaco-therapeutic intervention.
Methods:
Twenty-five early abstinent cocaine-dependent individuals were administered a battery of neurocognitive tasks on entry into treatment (baseline) and again following 3 weeks of either placebo or guanfacine treatment (up to 3 mg). Tasks included: Stop Signal, Stroop, 3-Dimentional Intra-dimensional/Extra-dimensional (IDED) task, Spatial Working Memory (SWM), Paired Associates Learning (PAL), Verbal Fluency and the Rey Auditory Verbal Learning Test (RAVLT).
Results:
Compared with placebo, the guanfacine group demonstrated attenuated anxiety and negative affect as well as improved performance on selective executive tests. This included fewer directional errors on the stop signal task, fewer errors on the extra-dimensional shift component of the IDED task and better attentional switching during verbal fluency. Guanfacine did not improve strategic working memory or peripheral memory.
Conclusion:
Guanfacine improves selective cognitive processes which may underlie salient treatment-related regulatory behaviors. Alpha2 agonists may therefore represent important agents for cocaine dependence.
AhmadiJKampmanKDackisC (2006) Outcome predictors in cocaine dependence treatment trials. Am J Addict15: 434–439.
2.
AlexanderJKHillierASmithRM. (2007) Beta-adrenergic modulation of cognitive flexibility during stress. J Cogn Neurosci19: 468–478.
3.
Ambrose-LanciLMSterlingRCVan BockstaeleEJ (2010) Cocaine withdrawal-induced anxiety in females: Impact of circulating estrogen and potential use of delta-opioid receptor agonists for treatment. J Neurosci Res88: 816–824.
ArnstenAFContantTA (1992) Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology (Berl)108: 159–169.
7.
ArnstenAFGoldman-RakicPS (1985) Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science230: 1273–1276.
8.
ArnstenAFGoldman-RakicPS (1990) Analysis of alpha-2 adrenergic agonist effects on the delayed nonmatch-to-sample performance of aged rhesus monkeys. Neurobiol Aging11: 583–590.
9.
ArnstenAFJinLE (2012) Guanfacine for the treatment of cognitive disorders: A century of discoveries at Yale. Yale J Biol Med85: 45–58.
10.
ArnstenAFLiBM (2005) Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions. Biol Psychiatry57: 1377–1384.
11.
ArnstenAFCaiJXGoldman-RakicPS (1988) The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. J Neurosci8: 4287–4298.
12.
Aston-JonesGCohenJD (2005) Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J Comp Neurol493: 99–110.
13.
Aston-JonesGGoldJI (2009) How we say no: Norepinephrine, inferior frontal gyrus, and response inhibition. Biol Psychiatry65: 548–549.
14.
BariAMarACTheobaldDE. (2011) Prefrontal and monoaminergic contributions to stop-signal task performance in rats. J Neurosci31: 9254–9263.
15.
BariARobbinsTW (2013) Inhibition and impulsivity: Behavioral and neural basis of response control. Prog Neurobiol108: 44–79.
16.
BarryDBatesMELabouvieE (2008) FAS and CFL forms of verbal fluency differ in difficulty: A meta-analytic study. Appl Neuropsychol15: 97–106.
17.
BearnJGossopMStrangJ (1996) Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend43: 87–91.
18.
BegeerSWierdaMScheerenAM. (2014) Verbal fluency in children with autism spectrum disorders: Clustering and switching strategies. Autism18: 1014-1018.
BeversdorfDQWhiteDMCheverDC. (2002) Central beta-adrenergic modulation of cognitive flexibility. Neuroreport13: 2505–2507.
21.
BillieuxJLagrangeGVan der LindenM. (2012) Investigation of impulsivity in a sample of treatment-seeking pathological gamblers: A multidimensional perspective. Psychiatry Res198: 291–296.
22.
BissonetteGBMartinsGJFranzTM. (2008) Double dissociation of the effects of medial and orbital prefrontal cortical lesions on attentional and affective shifts in mice. J Neurosci28: 11124–11130.
23.
BlumeAWMarlattGA (2009) The role of executive cognitive functions in changing substance use: What we know and what we need to know. Ann Behav Med37: 117–125.
24.
BollaKILindgrenKNBonaccorsyC. (1990) Predictors of verbal fluency (FAS) in the healthy elderly. J Clin Psychol46: 623–628.
25.
BreversDCleeremansAVerbruggenF. (2012) Impulsive action but not impulsive choice determines problem gambling severity. PLoS One7: e50647.
26.
BrewerJAWorhunskyPDCarrollKM. (2008) Pretreatment brain activation during Stroop task is associated with outcomes in cocaine-dependent patients. Biol Psychiatry64: 998–1004.
27.
CarrollKMKilukBDNichC. (2011) Cognitive function and treatment response in a randomized clinical trial of computer-based training in cognitive-behavioral therapy. Subst Use Misuse46: 23–34.
28.
CecchiMKhoshboueiHMorilakDA (2002) Modulatory effects of norepinephrine, acting on alpha 1 receptors in the central nucleus of the amygdala, on behavioral and neuroendocrine responses to acute immobilization stress. Neuropharmacology43: 1139–1147.
29.
ChampodASPetridesM (2007) Dissociable roles of the posterior parietal and the prefrontal cortex in manipulation and monitoring processes. Proc Natl Acad Sci U S A104: 14837–14842.
30.
ChappellPBRiddleMAScahillL. (1995) Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry34: 1140–1146.
31.
ChildressAC (2012) Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Adv Ther29: 385–400.
32.
ClerkinSMSchulzKPHalperinJM. (2009) Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals. Biol Psychiatry66: 307–312.
33.
ColzatoLSHuizingaMHommelB (2009) Recreational cocaine polydrug use impairs cognitive flexibility but not working memory. Psychopharmacology (Berl)207: 225–234.
34.
ColzatoLSvan den WildenbergWPHommelB (2007) Impaired inhibitory control in recreational cocaine users. PLoS One2: e1143.
35.
CoolsRBarkerRASahakianBJ. (2001) Mechanisms of cognitive set flexibility in Parkinson’s disease. Brain124: 2503–2512.
36.
De OliveiraLGBarrosoLPSilveiraCM. (2009) Neuropsychological assessment of current and past crack cocaine users. Subst Use Misuse44: 1941–1957.
37.
DecampEClarkKSchneiderJS (2011) Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates. Eur J Neurosci34: 1018–1022.
38.
DianaM (2011) The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry2: 64.
39.
DiasRRobbinsTWRobertsAC (1996) Primate analogue of the Wisconsin Card Sorting Test: Effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci110: 872–886.
40.
EagleDMBariARobbinsTW (2008) The neuropsychopharmacology of action inhibition: Cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl)199: 439–456.
41.
EngbergGErikssonE (1991). Effects of alpha2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats. Naunyn Schmiedebergs Arch Pharmacol. 343: 472–7.
ErbSShahamYStewartJ (1998) The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci18: 5529–5536.
44.
FaraoneSVBiedermanJSpencerT. (2005) Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: A drug-placebo response curve analysis. Behav Brain Funct1: 16.
45.
FassbenderCMurphyKFoxeJJ. (2004) A topography of executive functions and their interactions revealed by functional magnetic resonance imaging. Brain Res Cogn Brain Res20: 132–143.
46.
Fernandez-SerranoMJPerez-GarciaMPeralesJC. (2010) Prevalence of executive dysfunction in cocaine, heroin and alcohol users enrolled in therapeutic communities. Eur J Pharmacol626: 104–112.
47.
FillmoreMTRushCR (2002) Impaired inhibitory control of behavior in chronic cocaine users. Drug Alcohol Depend66: 265–273.
48.
FirstMSpitzerRGibbonM. (1995) Structured Clinical Interview for DSM-IV. Patient Edition. Washington DC: American Psychiatric Press Inc.
49.
FishbeinDHHerman-StahlMEldrethD. (2006) Mediators of the stress-substance-use relationship in urban male adolescents. Prev Sci7: 113–126.
50.
FoxHCAxelrodSRPaliwalP. (2007a) Difficulties in emotion regulation and impulse control during cocaine abstinence. Drug Alcohol Depend89: 298–301.
51.
FoxHCBergquistKLHongKI. (2007b) Stress-induced and alcohol cue-induced craving in recently abstinent alcohol-dependent individuals. Alcohol Clin Exp Res31: 395–403.
52.
FoxHCMorganPTSinhaR (2014) Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals. Neuropsychopharmacology39: 1527–1537.
53.
FoxHCSeoDTuitK. (2012) Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings. J Psychopharmacol26: 958–972.
54.
GaravanHHesterR (2007) The role of cognitive control in cocaine dependence. Neuropsychol Rev17: 337–345.
55.
GauSSShangCY (2010) Improvement of executive functions in boys with attention deficit hyperactivity disorder: An open-label follow-up study with once-daily atomoxetine. Int J Neuropsychopharmacol13: 243–256.
56.
GishECMillerJLHoneyBL. (2010) Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother44: 343–351.
57.
GoldenCJ (1975) A group version of the Stroop Color and Word Test. J Pers Assess39: 386–388.
58.
GonzalezGSevarinoKSofuogluM. (2003) Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: Results of a randomized pilot study. Addiction98: 1625–1632.
59.
HampshireAOwenAM (2006) Fractionating attentional control using event-related fMRI. Cereb Cortex16: 1679–1689.
60.
HaneyMGundersonEWJiangH. (2010) Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry67: 59–65.
61.
HesterRD’EspositoMColeMW. (2007) Neural mechanisms for response selection: Comparing selection of responses and items from working memory. Neuroimage34: 446–454.
62.
HesterRLMurphyKFoxeJJ. (2004) Predicting success: Patterns of cortical activation and deactivation prior to response inhibition. J Cogn Neurosci16: 776–785.
HuntRDArnstenAFAsbellMD (1995) An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry34: 50–54.
65.
IjffDMAldenkampAP (2013) Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol111: 707–718.
66.
JakalaPRiekkinenMSirvioJ. (1999a) Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology20: 460–470.
67.
JakalaPRiekkinenMSirvioJ. (1999b) Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers. Neuropsychopharmacology21: 495–502.
68.
JarrottBLouisWJSummersRJ (1982) [3H]-guanfacine: A radioligand that selectively labels high affinity alpha2-adrenoceptor sites in homogenates of rat brain. Br J Pharmacol75: 401–408.
69.
JiXHJiJZZhangH. (2008) Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat. Neuropsychopharmacology33: 2263–2271.
70.
KampmanKMPettinatiHMVolpicelliJR. (2004) Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. Am J Addict13: 74–82.
71.
KampmanKMVolpicelliJRMulvaneyF. (2002) Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. Addict Behav27: 251–260.
72.
KangSYKleinmanPHWoodyGE. (1991) Outcomes for cocaine abusers after once-a-week psychosocial therapy. Am J Psychiatry148: 630–635.
73.
KelleyBJYeagerKRPepperTH. (2007) The effect of propranolol on cognitive flexibility and memory in acute cocaine withdrawal. Neurocase13: 320–327.
74.
KenemansJLBekkerEMLijffijtM. (2005) Attention deficit and impulsivity: Selecting, shifting, and stopping. Int J Psychophysiol58: 59–70.
75.
LeADFunkDJuzytschW. (2011) Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology (Berl)218: 89–99.
76.
LiCSMilivojevicVKempK. (2006) Performance monitoring and stop signal inhibition in abstinent patients with cocaine dependence. Drug Alcohol Depend85: 205–212.
77.
LoganGDCowanWBDavisKA (1984) On the ability to inhibit simple and choice reaction time responses: A model and a method. J Exp Psychol Hum Percept Perform10: 276–291.
78.
LoreaIFernandez-MontalvoJTirapu-UstarrozJ. (2010) [Neuropsychological performance in cocaine addiction: A critical review]. Rev Neurol51: 412–426.
79.
MacDonaldEKobilkaBKScheininM (1997) Gene targeting – homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci18: 211–219.
80.
McNairDMLorrMDroppelmanLF (1971) Manual for the Profile of Mood States. San Diego: Educational and industrial Testing Service.
81.
MercerDEWoodyGE (1999) Therapy Manuals for Drug Addiction Series: Individual Drug Counseling. Maryland: US Department of Health and Human Services. NIH Pub. No. 99–4380.
82.
MischelW (2004) Toward an integrative science of the person. Annu Rev Psychol55: 1–22.
83.
Mosqueda-GarciaR (1990) Guanfacine: A second generation alpha 2-adrenergic blocker. Am J Med Sci299: 73–76.
84.
NaifehJATullMTGratzKL (2012) Anxiety sensitivity, emotional avoidance, and PTSD symptom severity among crack/cocaine dependent patients in residential treatment. Cognit Ther Res36: 247–257.
85.
NiggJT (2001) Is ADHD a disinhibitory disorder?Psychol Bull127: 571–598.
86.
NiggJTSilkKRStavroG. (2005) Disinhibition and borderline personality disorder. Dev Psychopathol17: 1129–1149.
87.
O’BrienMSAnthonyJC (2005) Risk of becoming cocaine dependent: Epidemiological estimates for the United States, 2000–2001. Neuropsychopharmacology30: 1006–1018.
88.
O’LearyTARohsenowDJMartinR. (2000) The relationship between anxiety levels and outcome of cocaine abuse treatment. Am J Drug Alcohol Abuse26: 179–194.
89.
RamaPLinnankoskiITanilaH. (1996) Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacol Biochem Behav55: 415–422.
90.
RamanujamVMAndersonKEGradyJJ. (2011) Riboflavin as an oral tracer for monitoring compliance in clinical research. Open Biomark J2011: 1–7.
91.
ReyA (1964) L’examinen clinique en psychologie. Paris: Presses Universitaires de France.
92.
RobertsDC (2005) Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol Behav86: 18–20.
93.
RobertsDCBrebnerK (2000) GABA modulation of cocaine self-administration. Ann N Y Acad Sci909: 145–158.
94.
Rodriguez-JimenezRAvilaCJimenez-ArrieroMA. (2006) Impulsivity and sustained attention in pathological gamblers: Influence of childhood ADHD history. J Gambl Stud22: 451–461.
95.
RogersRDAndrewsTCGrasbyPM. (2000) Contrasting cortical and subcortical activations produced by attentional-set shifting and reversal learning in humans. J Cogn Neurosci12: 142–162.
96.
SahakianBJMorrisRGEvendenJL. (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson’s disease. Brain111 ( Pt 3): 695–718.
97.
SalleeFRKollinsSHWigalTL (2012) Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol22: 206–214.
98.
Sanchez-HervasELlorente del PozoJM (2012) [Relapse in cocaine addiction: a review]. Adicciones24: 269–279.
99.
ScahillLChappellPBKimYS. (2001) A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry158: 1067–1074.
100.
SeedatYK (1985) Clonidine and guanfacine – comparison of their effects on haemodynamics in hypertension. S Afr Med J67: 557–559.
101.
SendereckaMGrabowskaASzewczykJ. (2012) Response inhibition of children with ADHD in the stop-signal task: An event-related potential study. Int J Psychophysiol85: 93–105.
102.
ShahamYShalevULuL. (2003) The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology (Berl)168: 3–20.
103.
ShangCYGauSS (2012) Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol22: 353–363.
104.
ShieldsADWangQWinderDG (2009) Alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience163: 339–351.
105.
SinhaR (2001) How does stress increase risk of drug abuse and relapse?Psychopharmacology (Berl)158: 343–359.
106.
SinhaRFoxHCHongKA. (2009) Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacology34: 1198–1208.
107.
SinhaRFoxHCHongKI. (2011) Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry68: 942–952.
SofuogluMDeVitoEEWatersAJ. (2013) Cognitive enhancement as a treatment for drug addictions. Neuropharmacology64: 452–463.
110.
SommerBRMitchellELWroolieTE. (2013) Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity. Ther Adv Neurol Disord6: 211–227.
111.
SorkinEMHeelRC (1986) Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs31: 301–336.
112.
StreeterCCTerhuneDBWhitfieldTH. (2008) Performance on the Stroop predicts treatment compliance in cocaine-dependent individuals. Neuropsychopharmacology33: 827–836.
113.
SummersRJJarrottBLouisWJ (1981) Comparison of [3H]clonidine and [3H]guanfacine binding to alpha 2 adrenoceptors in membranes from rat cerebral cortex. Neurosci Lett25: 31–36.
114.
SwannNCTandonNPietersTA. (2013) Intracranial electroencephalography reveals different temporal profiles for dorsal- and ventro-lateral prefrontal cortex in preparing to stop action. Cereb Cortex23: 2479–2488.
115.
SwartzBEMcDonaldCRPatelA. (2008) The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls. Clin Neuropharmacol31: 251–260.
116.
ThanosPKTaintorNBRiveraSN. (2004) DRD2 gene transfer into the nucleus accumbens core of the alcohol preferring and nonpreferring rats attenuates alcohol drinking. Alcohol Clin Exp Res28: 720–728.
117.
TiceDMBratslavskyEBaumeisterRF (2001) Emotional distress regulation takes precedence over impulse control: If you feel bad, do it!J Pers Soc Psychol80: 53–67.
118.
TroyerAKMoscovitchMWinocurG (1997) Clustering and switching as two components of verbal fluency: Evidence from younger and older healthy adults. Neuropsychology11: 138–146.
119.
TroyerAKMoscovitchMWinocurG. (1998) Clustering and switching on verbal fluency tests in Alzheimer’s and Parkinson’s disease. J Int Neuropsychol Soc4: 137–143.
120.
TurnerMA (1999) Generating novel ideas: Fluency performance in high-functioning and learning disabled individuals with autism. J Child Psychol Psychiatry40: 189–201.
121.
TurnerTHLaRoweSHornerMD. (2009) Measures of cognitive functioning as predictors of treatment outcome for cocaine dependence. J Subst Abuse Treat37: 328–334.
122.
van HolstRJSchiltT (2011) Drug-related decrease in neuropsychological functions of abstinent drug users. Curr Drug Abuse Rev4: 42–56.
123.
Verdejo-GarciaAPerez-GarciaM (2007) Profile of executive deficits in cocaine and heroin polysubstance users: Common and differential effects on separate executive components. Psychopharmacology (Berl)190: 517–530.
124.
Verdejo-GarciaABetanzos-EspinosaPLozanoOM. (2012) Self-regulation and treatment retention in cocaine dependent individuals: A longitudinal study. Drug Alcohol Depend122: 142–148.
125.
VerricoCDHaileCNNewtonTF. (2013) Pharmacotherapeutics for substance-use disorders: A focus on dopaminergic medications. Expert Opin Investig Drugs.
126.
VitkovitchMBishopSDanceyC. (2002) Stroop interference and negative priming in patients with multiple sclerosis. Neuropsychologia40: 1570–1576.
127.
WangMRamosBPPaspalasCD. (2007) Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell129: 397–410.
128.
YeZAltenaENombelaC. (2014) Improving response inhibition in Parkinson’s disease with atomoxetine. Biol Psychiatry DOi: 10.1016/j.biopsych.2014.01.024. [Epub ahead of print].
